एक सफल शोध में, वैज्ञानिकों ने प्रदर्शित किया है कि एमिनोग्लाइकोसाइड्स (जेंटामाइसिन) एंटीबायोटिक का उपयोग पारिवारिक मनोभ्रंश के इलाज के लिए किया जा सकता है।
RSI एंटीबायोटिक दवाओं gentamicin, neomycin, streptomycin etc are commonly used to treat bacterial infections. These are broad spectrum एंटीबायोटिक दवाओं से संबंधित एमिनोग्लीकोसाइड्स वर्ग और विशेष रूप से ग्राम नकारात्मक बैक्टीरिया के खिलाफ सक्रिय हैं। वे जीवाणु राइबोसोम के साथ बंध कर कार्य करते हैं और अवरोध करते हैं प्रोटीन अतिसंवेदनशील में संश्लेषण जीवाणु.
But aminoglycosides are also known to induce mutation suppression in eukaryotes to produce full length protein. This is a lesser known function of this एंटीबायोटिक which has been used in the past to treat several human diseases such as Duchenne muscular dystrophy (DMD) [2]. Now, there is report that this function may be used in treating पागलपन साथ ही निकट भविष्य में।
In a paper published on 08 January 2020 in the journal, Human Molecular Genetics, the researchers of University of Kentucky have provided proof of concept that these एंटीबायोटिक दवाओं may be used to treat frontotemporal पागलपन [1]. This is an exciting breakthrough in science that has potential to improve quality of lives of several people with पागलपन.
पागलपन is a group of symptoms involving deterioration in ability to perform usual daily activities and is caused due to deterioration in cognitive function like memory, thinking or behavour. It is a major reason of disability and dependency among elderly people worldwide. It affects carers and families as well. According to an estimate, there are 50 million people with पागलपन worldwide with 10 million new cases every year. Alzheimer रोग का सबसे सामान्य रूप है पागलपन. Frontotemporal पागलपन is the second-most common form. This is early onset in nature and affects frontal and temporal lobes of the brain.
The patients with frontotemporal पागलपन have progressive atrophy of frontal and temporal lobes of the brain that leads to gradual deterioration of cognitive functions, language skills and personality and behavioral changes. This is heritable in nature caused by genetic mutations. As a result of these genetic mutations, the brain is unable to form a protein called progranulin. The insufficient production of progranulin in the brain in linked to this form of पागलपन.
In their study, the University of Kentucky researchers have found that if aminoglycoside एंटीबायोटिक दवाओं were added to the neuronal cells with progranulin mutations in an in vitro cell culture, they skip the mutation and form full length protein. The progranulin protein level was recovered up to about 50 to 60%. This finding supports the principle that aminoglycoside (gentamicin and G418) hold the treatment possibility for such patients.
Next step would be to move forward from ”in vitro cell culture model” to ”animal model”. The mutation suppression by aminoglycosides as a therapeutic strategy to treat frontotemporal पागलपन has come one step closer.
***
{आप उद्धृत स्रोतों की सूची में नीचे दिए गए डीओआई लिंक पर क्लिक करके मूल शोध पत्र पढ़ सकते हैं}
स्रोत (रों)
1. Kuang L., et al, 2020. Frontotemporal पागलपन nonsense mutation of progranulin rescued by aminoglycosides. Human Molecular Genetics, ddz280. DOI: https://doi.org/10.1093/hmg/ddz280
2. मलिक वी।, एट अल, 2010। ड्यूचेन मस्कुलर डिस्ट्रॉफी के लिए चिकित्सीय रणनीति के रूप में एमिनोग्लाइकोसाइड-प्रेरित उत्परिवर्तन दमन (स्टॉप कोडन रीडथ्रू)। न्यूरोलॉजिकल डिसऑर्डर (2010) 3 (6) 379389 में चिकित्सीय अग्रिम। डीओआई: https://doi.org/10.1177/1756285610388693
***
